Biological and Clinical Database for Pancreatic Adenocarcinoma (BACAP)
BACAP is a biobank dedicated to the pancreatic adenocarcinoma funded by institut national institue du cancer (INCa) and coordinated by Dr Barbara Bournet from Toulouse hospital. This base includes clinical data and biological samples such as blood, serum, plasma, saliva, DNA and RNA from tumors cells.
The mission of this prospective project is to make available to the scientific community a clinical biological base from patients with pancreatic adenocarcinoma
調査の概要
詳細な説明
Pancreatic cancer represents the fifth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is impossible due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.
The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy). The present project aims at creating a multicentre national network used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma, built on the best quality standards, for the biological resources as well as the associated clinical and epidemiological data.
The originality of this CBB relies on the fact that it will have not only tumour tissues sampled from surgical specimens of resectable tumours but also cell and biopsy material from unresectable and/or metastatic tumours sampled under endoscopic ultrasonography (1500 biopsies over 3 years coupled to systematic blood samples). Endoscopic ultrasonography is a technique used to specifically perform biopsies on pancreatic tumours and to obtain useful cell material for research. To these samples will be associated every clinical and epidemiological target data required for research projects related to this unique CBB in France. From these samples, DNA and RNA will be especially isolated, as it is a precious biological material for the programmed molecular analyses.
There are many stakes: creating a French network in order to form, with the prospective plans over 3 years, a collection of tissue, biopsies, nucleic acids from pancreatic cancer associated to circulating blood samples and relevant clinical data. Thanks to this collection, the investigator team hope to be able to identify new molecular markers (from cancer tissue and/or circulating blood from pancreatic cancer patients) applicable to clinical practice to diagnose, to assess the prognosis or to predict the response to pancreatic cancer chemotherapy. The investigator team will also try to identify new risk factors for this cancer, especially regarding the diet. The base will thus be made up from 12 different French centres from University Hospital and private Centres where gastroenterologists, oncologists, digestive surgeons, anatomopathologists, epidemiologists intervene as they are all associated to scientific teams dedicated to pancreatic cancer, itself already formed in collaborative networks.
Investigators hope through this project: to get a unique and exceptional CBB for pancreatic cancer, to reach the required standards (especially Inca) for this CBB, and to be internationally recognised. This base will be a strong guarantee to identify new molecular markers for the diagnosis, the prognosis, and the predictive response to chemotherapy for pancreatic cancer, especially when locally advanced. Finally, the epidemiological projects related to this project are originally about the nutritional issues (regardless of the lipid diet and the cachexia) associated to pancreatic cancer.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Bordeaux、フランス、33604
- 募集
- University Hospital Bordeaux
-
コンタクト:
- Véronique VENDRELY., MD
- メール:veronique.vendrely@chu-bordeaux.fr
-
Clichy La Garenne、フランス、92110
- 募集
- Beaujon Hospital
-
コンタクト:
- Pascal HAMMEL, MD; PHD
- メール:pascal.hammel@aphp.fr
-
Lille、フランス、59037
- 募集
- University Hospital Lille
-
コンタクト:
- Stéphanie TRUANT, MD; PHD
- メール:Stephanie.TRUANT@CHRU-LILLE.FR
-
Lille、フランス、59037
- 募集
- University Hospital of Lille
-
コンタクト:
- Guillaume PIESSEN, MD; PHD
- メール:Guillaume.PIESSEN@CHRU-LILLE.FR
-
Lyon、フランス、69008
- 募集
- Centre Leon Berard
-
コンタクト:
- Pierre GUIBERT, MD
- メール:Pierre.GUIBERT@lyon.unicancer.fr
-
Lyon、フランス、69008
- 募集
- Private Hospital Jean Mermoz
-
コンタクト:
- Bertrand NAPOLEON
- メール:bertrand.napoleon@dartybox.com
-
Marseille、フランス、13000
- 募集
- Hôpital La Timone
-
コンタクト:
- Jean-François SEITZ, MD; PHD
- メール:Jean-francois.SEITZ@ap-hm.fr
-
Marseille、フランス、13000
- 募集
- Hospital Nord
-
コンタクト:
- Stéphane GARCIA
- メール:Stephane.GARCIA@ap-hm.fr
-
Montpellier、フランス、34000
- 募集
- Institut Régional du Cancer de Montpellier
-
コンタクト:
- Fréderic BIBEAU, MD; PHD
- メール:Frederic.Bibeau@icm.unicancer.fr
-
Montpellier、フランス、34000
- 募集
- University Hospital Montpellier
-
コンタクト:
- Eric ASSENAT, MD, PHD
- メール:e-assenat@chu-montpellier.fr
-
Nice、フランス、06202
- 募集
- University Hospital of Nice
-
コンタクト:
- Geoffroy VANBIERVLIET, MD; PHD
- メール:vanbiervliet.g@chu-nice.fr
-
Paris、フランス、75010
- 募集
- Saint-Louis Hospital
-
コンタクト:
- Dominique FARGE-BANCEL, MD, PHD
- メール:dominique.farge-bancel@aphp.fr
-
Paris、フランス、75016
- 募集
- Clinique du Trocadero
-
コンタクト:
- Laurent PALAZZO, MD
- メール:laurent.palazzo@wanadoo.fr
-
Pau、フランス、64000
- 募集
- PAU hospital
-
コンタクト:
- Philippe BERTHELEMY, MD
- メール:philippe.berthelemy@ch-pau.fr
-
Toulouse、フランス、31059
- 募集
- University Hospital Toulouse
-
コンタクト:
- Louis BUSCAIL, MD; PHD
- メール:buscail.l@chu-toulouse.fr
-
Villejuif、フランス、94805
- 募集
- Institut Gustave Roussy
-
コンタクト:
- Jean-Yves SCOAZEC, MD; PHD
- メール:Jean-yves.SCOAZEC@gustaveroussy.fr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Patient eighteen years old
- Histologically or cytologically confirmed pancreatic adenocarcinoma
- Solid pancreatic mass explored with tomodensitometry or endoscopic ultrasonography fine-needle aspiration
- Informed consent signed
Exclusion Criteria:
- no informed consent
- pregnancy women
- no histologically or cytologically confirmed pancreatic adenocarcinoma
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
Cohort
Collection of biological samples
|
Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Constitution of a transdisciplinary biobank with collection of biological samples with DNA
時間枠:Through the study completion, an average of 11 months
|
The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma
|
Through the study completion, an average of 11 months
|
Constitution of a transdisciplinary biobank with collection of biological samples without DNA
時間枠:Through the study completion, an average of 11 months
|
The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma
|
Through the study completion, an average of 11 months
|
協力者と研究者
捜査官
- 主任研究者:Barbara BOURNET, MD; PHD、University Hospital, Toulouse
出版物と役立つリンク
一般刊行物
- Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel). 2020 Mar 25;12(4):783. doi: 10.3390/cancers12040783.
- Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D; BACAP Consortium. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Gastroenterology. 2020 Apr;158(5):1346-1358.e4. doi: 10.1053/j.gastro.2019.12.009. Epub 2019 Dec 14.
- Canivet C, Gourgou-Bourgade S, Napoleon B, Palazzo L, Flori N, Guibert P, Piessen G, Farges-Bancel D, Seitz JF, Assenat E, Vendrely V, Truant S, Vanbiervliet G, Berthelemy P, Garcia S, Gomez-Brouchet A, Buscail L, Bournet B; BACAP Consortium. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. BMC Cancer. 2018 Oct 16;18(1):986. doi: 10.1186/s12885-018-4906-4.
便利なリンク
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
膵臓腺癌の臨床試験
-
Washington University School of MedicineUniversity of Oklahoma Medical Center; Northwestern University Chicago Illinois; Saint Luke's...完了